126 related articles for article (PubMed ID: 11449333)
1. Viral safety of B-domain deleted recombinant factor VIII.
Charlebois TS; O'connell BD; Adamson SR; Brink-Nilsson H; Jernberg M; Eriksson B; Kelley BD
Semin Hematol; 2001 Apr; 38(2 Suppl 4):32-9. PubMed ID: 11449333
[TBL] [Abstract][Full Text] [Related]
2. The manufacturing process for B-domain deleted recombinant factor VIII.
Eriksson RK; Fenge C; Lindner-Olsson E; Ljungqvist C; Rosenquist J; Smeds AL; östlin A; Charlebois T; Leonard M; Kelley BD; Ljungqvist A
Semin Hematol; 2001 Apr; 38(2 Suppl 4):24-31. PubMed ID: 11449332
[TBL] [Abstract][Full Text] [Related]
3. Viral safety of recombinant factor IX.
Adamson S; Charlebois T; O'Connell B; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
[TBL] [Abstract][Full Text] [Related]
4. B-domain deleted recombinant factor VIII formulation and stability.
Osterberg T; Fatouros A; Neidhardt E; Warne N; Mikaelsson M
Semin Hematol; 2001 Apr; 38(2 Suppl 4):40-3. PubMed ID: 11449334
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII.
Kelley BD; Tannatt M; Magnusson R; Hagelberg S; Booth J
Biotechnol Bioeng; 2004 Aug; 87(3):400-12. PubMed ID: 15281114
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
[TBL] [Abstract][Full Text] [Related]
7. Production processes of licensed recombinant factor VIII preparations.
Boedeker BG
Semin Thromb Hemost; 2001 Aug; 27(4):385-94. PubMed ID: 11547361
[TBL] [Abstract][Full Text] [Related]
8. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
Josephson CD; Abshire T
Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
[TBL] [Abstract][Full Text] [Related]
9. The concern of viral safety in the treatment of hemophilia.
Berntorp E
Semin Hematol; 2001 Apr; 38(2 Suppl 4):1-3. PubMed ID: 11449329
[No Abstract] [Full Text] [Related]
10. Recombinate: viral safety and final product manufacturing testing and specifications.
Lawrence J
Ann Hematol; 1994; 68 Suppl 3():S21-4. PubMed ID: 8180253
[No Abstract] [Full Text] [Related]
11. [Production of factor VIII by genetic techniques].
Neutzling O
Beitr Infusionsther; 1993; 31():38-43. PubMed ID: 7693262
[TBL] [Abstract][Full Text] [Related]
12. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
[TBL] [Abstract][Full Text] [Related]
13. The manufacturing process of recombinant factor VIII, recombinate.
Gomperts E; Lundblad R; Adamson R
Transfus Med Rev; 1992 Oct; 6(4):247-51. PubMed ID: 1421823
[TBL] [Abstract][Full Text] [Related]
14. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely?
Suiter TM
Semin Thromb Hemost; 2002 Jun; 28(3):277-84. PubMed ID: 12098089
[TBL] [Abstract][Full Text] [Related]
15. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.
Afonja O; Kozak R; Petraro P; Michaels LA; Mathew P; Lemm G; Kessler C
Expert Rev Hematol; 2016 Dec; 9(12):1151-1164. PubMed ID: 27841041
[TBL] [Abstract][Full Text] [Related]
16. Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule.
Ahmadian H; Hansen EB; Faber JH; Sejergaard L; Karlsson J; Bolt G; Hansen JJ; Thim L
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):568-75. PubMed ID: 26761578
[TBL] [Abstract][Full Text] [Related]
17. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional characterization of B-domain deleted recombinant factor VIII.
Sandberg H; Almstedt A; Brandt J; Castro VM; Gray E; Holmquist L; Lewin M; Oswaldsson U; Mikaelsson M; Jankowski MA; Bond M; Scoble HA
Semin Hematol; 2001 Apr; 38(2 Suppl 4):4-12. PubMed ID: 11449330
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients.
Courter SG; Bedrosian CL
Semin Hematol; 2001 Apr; 38(2 Suppl 4):44-51. PubMed ID: 11449335
[TBL] [Abstract][Full Text] [Related]
20. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.
Kessler CM; Gill JC; White GC; Shapiro A; Arkin S; Roth DA; Meng X; Lusher JM
Haemophilia; 2005 Mar; 11(2):84-91. PubMed ID: 15810908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
